Health Partners, the UK's largest non-hospital private healthcare service provider with over 2 million patients across more than 550 commercial, insurance and government customers, partners with MedX after successfully piloting MedX's DermSecure I have announced my intentions.® screening platform.
Mississauga, Ontario, February 28, 2024–(Business Wire)–Medex Health Corporation (“Medox” or “company“) (TSXV: MDX), a global leader in teledermatology, is pleased to announce the successful completion of a pilot project with Health Partners. MedX and Health Partners are working together to begin rolling out this service to targeted customers who are committed to a proactive approach to healthcare management.
Health Partners Group Limited (“health partner) is a reputable private sector health, treatment and primary care services company in the UK, serving a broad customer base of businesses, government bodies, insurance companies, health trusts, pension funds and individuals. Health Partners employs over 1,000 people and operates telehealth, mobile and on-site operations across the UK and Republic of Ireland.
Skin cancer is one of the most commonly diagnosed cancers in the UK, with more than 220,000 people diagnosed each year and the number continues to rise. According to the UK Cancer Alliance, outdoor workers are exposed to five to 10 times more sunlight, resulting in an average 60% higher risk of developing skin cancer. The COVID-19 pandemic has delayed access to health care. As reported in the Journal of the American Medical Association, restrictions on medical professionals, staff shortages, and fear of SARS-CoV-2 infection have disrupted routine medical care, including early detection of melanoma. Melanoma is the most deadly skin cancer, but early detection can significantly improve patient outcomes. According to Cancer Research UK, his five-year survival rate for patients diagnosed with stage 1-2 melanoma is 99%. The five-year survival rate for patients diagnosed with stage 4 melanoma drops to 30% if it is left undetected.
“Health Partners is uniquely positioned to offer dermatologist-rated skin cancer screening to at-risk patients in the workplace as part of full-time employee health plan assessments. Successful Pilot with MedX SIAscope® Devices and DermSecure® This platform has demonstrated the efficiency and ease of access to this potentially lifesaving service,” said Mike Druhan, president of MedX Dermatology Services.
“Health Partners' clinical teams continually strive to identify cutting-edge innovations that provide the highest level of support to our more than 2 million patients,” said Andrew Health Partners, Managing Director. Noble said. “This pilot demonstrated that MedX’s cutting-edge skin assessment technology allows dermatologists to quickly and accurately assess pigmented lesions and moles remotely. We are proud to provide our clients with targeted and life-changing services.”
About Health Partners Group Co., Ltd.:
Health Partners, headquartered in East Sussex, UK, is a leading health and wellbeing company, providing a full range of corporate health, treatment and primary care services to businesses, governments, insurers, health trusts, pension funds and families. . They combine expert advice and clinical services with a marketing-leading platform to deliver customized, impact-driven health programs to improve people's well-being and performance.
Health Partners is recognized as one of the UK's leading corporate healthcare providers and holds numerous accreditation, certificates and memberships including ISO27001, CQC and SEQOHS. Health Partners operates in the United Kingdom and the Republic of Ireland, serving more than 2 million people in organizations across a variety of industries. For more information, please visit http://www.healthpartnersgroup.com.
MedX Health Corp.:
MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with SIAscopy.® About DermSecure® Telemedicine platform using SIAscopy® technology. SIAscopy® Also included in SIAMETRICS products®Simsis®mall mate®, MedX is manufactured in an ISO 13485 certified facility.Cymetrics®Simsis®mall mate® This includes a handheld device that uses patented technology that utilizes light and its transmission to painlessly and non-invasively view suspicious moles or lesions up to 2 mm below. The software creates real-time images for evaluation by doctors and dermatologists. Removes all types of moles and lesions within seconds. These products are approved for use in Canada, the United States, Australia, New Zealand, the European Union, Brazil, and Turkey by Health Canada, the U.S. Food and Drug Administration, the Drug Administration, and Conformité Européenne. Visit https://medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This media release may contain forward-looking statements that reflect the Company's current expectations regarding future events. Forward-looking statements involve risks and uncertainties.
View source version on businesswire.com. https://www.businesswire.com/news/home/20240228237603/ja/
contact address
Bill Mitoulas, Investor Relations
Medex Health Corporation
bill@medxhealth.com
+1-416-479-9547
